1492 Capital Management’s Fennec Pharmaceuticals FENC Stock Holding History

1492 Capital Management’s Portfolio FENC Stock Details FENC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$700K	Buy	65,149 +14,444	+28%	+$118K	0.21%	80
2026 Q1	$312K	Buy	50,705 +22,613	+80%	+$175K	0.12%	103
2025 Q4	$216K	Buy	+28,092	New	+$231K	0.08%	107
2023 Q2	–	Sell	-94,839	Closed	-$789K	–	104
2023 Q1	$789K	Sell	94,839 -31	-0%	-$288	0.49%	64
2022 Q4	$911K	Buy	+94,870	New	+$839K	0.59%	55

Other funds holding FENC

Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

SCM

Solas Capital Management Darien, Connecticut $187M AUM 12.91% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PCA

Prospect Capital Advisors Sausalito, California $220M AUM 60.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

1492 Capital Management's FENC Position: Q2 2026 in Review

1492 Capital Management increased its Fennec Pharmaceuticals (FENC) stake by 28% in Q2 2026, buying an estimated $118K and bringing the position to 65,149 shares worth $700K. The position accounts for 0.21% of the portfolio, ranked #80.

1492 Capital Management first reported a position in FENC in Q4 2022 and has held it in 5 quarters since. The position peaked at $911K in Q4 2022. 105 funds tracked by Wall St. Rank hold FENC as of Q2 2026.

1492 Capital Management held 65,149 shares of Fennec Pharmaceuticals worth $700K as of Q2 2026.
1492 Capital Management bought 14,444 Fennec Pharmaceuticals shares in Q2 2026, an estimated $118K.
Fennec Pharmaceuticals made up 0.21% of 1492 Capital Management's portfolio in Q2 2026, its #80 holding.
1492 Capital Management first reported a position in Fennec Pharmaceuticals in Q4 2022 and has held it in 5 quarters since.
1492 Capital Management's Fennec Pharmaceuticals position peaked at $911K in Q4 2022.
105 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q2 2026.

Based on 1492 Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.